461 related articles for article (PubMed ID: 33475317)
1. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
[TBL] [Abstract][Full Text] [Related]
2. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
[TBL] [Abstract][Full Text] [Related]
3. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
[TBL] [Abstract][Full Text] [Related]
4. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
[TBL] [Abstract][Full Text] [Related]
5. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
[TBL] [Abstract][Full Text] [Related]
6.
Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
8. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
10. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
[TBL] [Abstract][Full Text] [Related]
11. Radiological model based on the standard magnetic resonance sequences for detecting methylguanine methyltransferase methylation in glioma using texture analysis.
Huang WY; Wen LH; Wu G; Pang PP; Ogbuji R; Zhang CC; Chen F; Zhao JN
Cancer Sci; 2021 Jul; 112(7):2835-2844. PubMed ID: 33932065
[TBL] [Abstract][Full Text] [Related]
12. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive O
Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
[TBL] [Abstract][Full Text] [Related]
15. Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.
Kanekar S; Zacharia BE
Radiol Clin North Am; 2021 May; 59(3):305-322. PubMed ID: 33926679
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
17. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
18. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
20. Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.
Chen L; Zhang H; Lu J; Thung K; Aibaidula A; Liu L; Chen S; Jin L; Wu J; Wang Q; Zhou L; Shen D
IEEE Trans Med Imaging; 2018 Aug; 37(8):1775-1787. PubMed ID: 29994582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
